

Laure Marignol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3679112/publications.pdf>

Version: 2024-02-01

94
papers

1,707
citations

279798

23
h-index

302126

39
g-index

100
all docs

100
docs citations

100
times ranked

3292
citing authors

#	ARTICLE	IF	CITATIONS
1	PO-1054 Cancer community perceptions and knowledge of Radiation Therapy as a cancer treatment. <i>Radiotherapy and Oncology</i> , 2022, 170, S889-S890.	0.6	0
2	Geometric and Dosimetric Evaluation of a Commercially Available Auto-segmentation Tool for Gross Tumour Volume Delineation in Locally Advanced Non-small Cell Lung Cancer: a Feasibility Study. <i>Clinical Oncology</i> , 2021, 33, 155-162.	1.4	4
3	Mini review: Personalization of the radiation therapy management of prostate cancer using MRI-based radiomics. <i>Cancer Letters</i> , 2021, 498, 210-216.	7.2	9
4	Influence of inter-observer delineation variability on radiomic features of the parotid gland. <i>Physica Medica</i> , 2021, 82, 240-248.	0.7	4
5	PO-1509 Tumours have a sex-relevance to the multifunctional oncoprotein Y-box binding protein-1 (YB-1). <i>Radiotherapy and Oncology</i> , 2021, 161, S1236-S1237.	0.6	0
6	PO-1800 Exploring hypoxia in prostate cancer with T2-weighted MRI radiomics and pimonidazole scoring.. <i>Radiotherapy and Oncology</i> , 2021, 161, S1526-S1527.	0.6	0
7	Sex in Bladder cancer research: an overview. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 548-553.	0.6	0
8	YB-1: The key to personalised prostate cancer management?. <i>Cancer Letters</i> , 2020, 490, 66-75.	7.2	13
9	The radiotherapy cancer patient: female inclusive, but male dominated. <i>International Journal of Radiation Biology</i> , 2020, 96, 851-856.	1.8	2
10	Pro-con of proton: Dosimetric advantages of intensity-modulation over passive scatter for thoracic malignancies. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2020, 15, 37-46.	1.9	7
11	Kidney Cancer Research: Sex-Inclusive but Sex-Unspecific. <i>Clinical Oncology and Research</i> , 2020, , 1-5.	0.0	0
12	PO-1845: Time trend analysis of target volume autocontouring in locally advanced NSCLC over the course of RT. <i>Radiotherapy and Oncology</i> , 2020, 152, S1027-S1028.	0.6	0
13	PO-1564: Influence of inter-observer delineation variability on radiomics features of the parotid gland. <i>Radiotherapy and Oncology</i> , 2020, 152, S847.	0.6	0
14	TMOD-12. ESTABLISHING A CLINICALLY RELEVANT MODEL OF MESENCHYMAL GLIOBLASTOMA (GBM) TO STUDY RESPONSE TO STANDARD OF CARE TREATMENT AND IMMUNE CHECKPOINT INHIBITION (ICI).. <i>Neuro-Oncology</i> , 2020, 22, ii230-ii230.	1.2	0
15	Dosimetric impact of uncorrected systematic yaw rotation in VMAT for peripheral lung SABR. <i>Reports of Practical Oncology and Radiotherapy</i> , 2019, 24, 520-527.	0.6	1
16	SP-036: Radiobiology of particles therapy: principles and latest advances. <i>Radiotherapy and Oncology</i> , 2019, 141, S15.	0.6	0
17	Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance. <i>Scientific Reports</i> , 2019, 9, 17325.	3.3	8
18	Nomograms are key decision-making tools in prostate cancer radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 283-292.	1.6	29

#	ARTICLE	IF	CITATIONS
19	Therapeutic potential of melatonin for breast cancer radiation therapy patients. <i>International Journal of Radiation Biology</i> , 2018, 94, 472-477.	1.8	23
20	Predicting Treatment Outcomes: The Case for Hypoxia Gene Signatures. <i>EBioMedicine</i> , 2018, 32, 3-4.	6.1	1
21	OC-0381: Lessons from isogenic models of radioresistant prostate cancer cells. <i>Radiotherapy and Oncology</i> , 2018, 127, S194-S195.	0.6	0
22	Planning target volume (PTV) margin practice patterns in adults and paediatrics among the Paediatric Radiation Oncology Society (PROS) members: an international survey. <i>Journal of Radiotherapy in Practice</i> , 2018, 17, 368-372.	0.5	0
23	Image-Guided Radiotherapy in Paediatrics: A Survey of International Patterns of Practice. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2018, 49, 265-269.	0.3	3
24	An overview on personalisation of radiotherapy prescriptions in locally advanced non-small cell lung cancer: Are we there yet?. <i>Radiotherapy and Oncology</i> , 2018, 128, 520-533.	0.6	4
25	Aspirin in the Management of Patients with Prostate Cancer Undergoing Radiotherapy: Friend or Foe?. <i>Anticancer Research</i> , 2018, 38, 1897-1902.	1.1	4
26	The Notch-1 receptor in prostate tumorigenesis. <i>Cancer Treatment Reviews</i> , 2017, 56, 36-46.	7.7	25
27	Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs. <i>Clinical and Translational Radiation Oncology</i> , 2017, 2, 63-68.	1.7	20
28	Metformin and improved treatment outcomes in radiation therapy – A review. <i>Cancer Treatment Reviews</i> , 2017, 55, 150-162.	7.7	35
29	The Notch-3 receptor: A molecular switch to tumorigenesis?. <i>Cancer Treatment Reviews</i> , 2017, 60, 69-76.	7.7	10
30	SP-0007: Gene editing: How this technique can be used to study radiation responses?. <i>Radiotherapy and Oncology</i> , 2017, 123, S1.	0.6	0
31	PV-0371: Novel molecular radiobiology for personalised prostate cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, S200.	0.6	0
32	Notch signalling: the true driver of small cell lung cancer?. <i>Translational Cancer Research</i> , 2017, 6, S1191-S1196.	1.0	5
33	⁶⁸ Ga-PSMA-PET/CT – as a Role in Detecting Prostate Cancer Lesions in Patients with Recurrent Disease. <i>Anticancer Research</i> , 2017, 37, 2753-2760.	1.1	10
34	Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis. , 2017, 37, 5343-5353.		50
35	Clinical Potential of Statins in Prostate Cancer Radiation Therapy. , 2017, 37, 5363-5372.		19
36	Low MiR-187 Expression Promotes Resistance to Chemoradiation Therapy In Vitro and Correlates with Treatment Failure in Patients with Esophageal Adenocarcinoma. <i>Molecular Medicine</i> , 2016, 22, 388-397.	4.4	29

#	ARTICLE	IF	CITATIONS
37	Hypoxia regulates Notch-3 mRNA and receptor activation in prostate cancer cells. <i>Heliyon</i> , 2016, 2, e00104.	3.2	10
38	EP-2042: Meta-analysis: can amifostine reduce chemoradiotherapy and radiotherapy toxicity in advanced NSCLC?. <i>Radiotherapy and Oncology</i> , 2016, 119, S964.	0.6	1
39	PO-0982: Therapeutic potential of the YB-1/Notch-3 interaction in prostate cancer. <i>Radiotherapy and Oncology</i> , 2016, 119, S477.	0.6	0
40	Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells. <i>Scientific Reports</i> , 2016, 6, 34796.	3.3	40
41	MGMT testing allows for personalised therapy in the temozolomide era. <i>Tumor Biology</i> , 2016, 37, 87-96.	1.8	27
42	Improving non-invasive detection of prostate cancer using diffusion-weighted MRI. <i>Advances in Modern Oncology Research</i> , 2016, 2, 309.	0.1	0
43	Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis. <i>Anticancer Research</i> , 2016, 36, 5-12.	1.1	82
44	EP-1237: Identification of MiRNAs associated with radioresistance in a prostate cancer model. <i>Radiotherapy and Oncology</i> , 2015, 115, S670.	0.6	0
45	PO-1061: Radiosensitisation properties of PI3K/AKT inhibitor GDC-0941 in prostate cancer cells. <i>Radiotherapy and Oncology</i> , 2015, 115, S572.	0.6	0
46	Identification of suitable endogenous controls for gene and miRNA expression studies in irradiated prostate cancer cells. <i>Tumor Biology</i> , 2015, 36, 6019-6028.	1.8	3
47	Clinical potential of boron neutron capture therapy for locally recurrent inoperable previously irradiated head and neck cancer. <i>Applied Radiation and Isotopes</i> , 2015, 106, 237-241.	1.5	9
48	Active surveillance for low-risk prostate cancer: diversity of practice across Europe. <i>Irish Journal of Medical Science</i> , 2015, 184, 305-311.	1.5	6
49	Abstract 3444: Identification of a miRNAs signature of radioresistance in a prostate cancer model. , 2015, , .		0
50	Threshold-based parametric analysis of diffusion-weighted magnetic resonance imaging at 3.0 Tesla to identify men with prostate cancer. <i>Advances in Modern Oncology Research</i> , 2015, 1, .	0.1	0
51	Radiotherapy scheduling using prime numbers. <i>Journal of Radiotherapy in Practice</i> , 2014, 13, 317-321.	0.5	0
52	OC-0587: An assessment of compassion fatigue levels among radiation therapists working in Ireland, using the proQOL-v5. <i>Radiotherapy and Oncology</i> , 2014, 111, S231.	0.6	0
53	Erratum to "Exposure to low dose ionizing radiation: Molecular and clinical consequences" [Cancer Lett. 338 (2) (2013) 209-218]. <i>Cancer Letters</i> , 2014, 349, 97.	7.2	1
54	Erythropoietin-stimulating agents and clinical outcomes in metastatic breast cancer patients with chemotherapy-induced anemia: a closed debate?. <i>Tumor Biology</i> , 2014, 35, 5095-5100.	1.8	5

#	ARTICLE	IF	CITATIONS
55	NUMB inhibition of NOTCH signalling as a therapeutic target in prostate cancer. Nature Reviews Urology, 2014, 11, 499-507.	3.8	85
56	Targeting notch in prostate cancer – combination is the key. Nature Reviews Urology, 2014, 11, 419-419.	3.8	6
57	Isogenic radiation resistant cell lines: Development and validation strategies. International Journal of Radiation Biology, 2014, 90, 115-126.	1.8	22
58	Exposure to low dose ionising radiation: Molecular and clinical consequences. Cancer Letters, 2014, 349, 98-106.	7.2	36
59	Exposure to low dose ionising radiation: Molecular and clinical consequences. Cancer Letters, 2013, 338, 209-218.	7.2	48
60	Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer. International Journal of Cancer, 2013, 132, 1771-1780.	5.1	40
61	Determining if low dose hyper-radiosensitivity (HRS) can be exploited to provide a therapeutic advantage: A cell line study in four glioblastoma multiforme (GBM) cell lines. International Journal of Radiation Biology, 2013, 89, 1009-1016.	1.8	24
62	Effect of ROI Selection on Pharmacokinetic parameter outputs from DCE-MRI in the prostate. Physica Medica, 2013, 29, 568-569.	0.7	0
63	DNA mismatch repair protein MSH2 dictates cellular survival in response to low dose radiation in endometrial carcinoma cells. Cancer Letters, 2013, 335, 19-25.	7.2	14
64	Exposure to hypoxia following irradiation increases radioresistance in prostate cancer cells. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1106-1116.	1.6	34
65	Gene expression analysis in prostate cancer: The importance of the endogenous control. Prostate, 2013, 73, 382-390.	2.3	13
66	Hypoxia, notch signalling, and prostate cancer. Nature Reviews Urology, 2013, 10, 405-413.	3.8	78
67	Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer. PLoS ONE, 2013, 8, e63723.	2.5	14
68	MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. Journal of Molecular Medicine, 2012, 90, 1449-1458.	3.9	93
69	Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 912-919.	1.6	16
70	EP-1111 USE OF DWI AND ADC VALUES IN DETECTION AND STAGING OF PROSTATE CANCER OF THE CENTRAL GLAND AND THE PERIPHERAL ZONE. Radiotherapy and Oncology, 2012, 103, S429.	0.6	0
71	147 DCEMRI IN ASSESSMENT OF TUMOR NEOVASCULARIZATION AFTER ANDROGEN-DEPRIVATION IN EXPERIMENTAL PROSTATE CANCER: CORRELATION TO QUANTITATIVE IMMUNOHISTOCHEMISTRY. Radiotherapy and Oncology, 2012, 102, S68.	0.6	0
72	Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer. Radiation Oncology, 2012, 7, 75.	2.7	25

#	ARTICLE	IF	CITATIONS
73	MicroRNAs as putative mediators of treatment response in prostate cancer. <i>Nature Reviews Urology</i> , 2012, 9, 397-407.	3.8	36
74	Standardization of assay methods reduces variability of total PSA measurements: an Irish study. <i>BJU International</i> , 2012, 110, 644-650.	2.5	15
75	Active surveillance for low-risk prostate cancer: Practice across Europe.. <i>Journal of Clinical Oncology</i> , 2012, 30, 217-217.	1.6	3
76	2041 DEMONSTRATION OF THE VARIABILITY OF THE DIFFERENT TOTAL PSA ASSAYS CURRENTLY IN USE THROUGHOUT IRISH HOSPITALS. <i>Journal of Urology</i> , 2011, 185, .	0.4	0
77	933 AN IN VITRO INVESTIGATION OF THE CYTOTOXIC AND RADIO-SENSITISING PROPERTIES OF A NOVEL MICRO- TUBULE TARGETING AGENT, PBOX-15, IN HYPOXIC PROSTATE CANCER CELL LINES. <i>European Urology Supplements</i> , 2011, 10, 292.	0.1	0
78	Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients. <i>Cancer Treatment Reviews</i> , 2011, 37, 643-654.	7.7	8
79	Androgen hypersensitivity in prostate cancer: Molecular perspectives on androgen deprivation therapy strategies. <i>Prostate</i> , 2011, 71, 550-557.	2.3	9
80	Comment on "Androgen hypersensitive preclinical model of prostate cancer" by Kawata et al.. <i>Prostate</i> , 2011, 71, 559-560.	2.3	0
81	Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro. <i>Cancer Biology and Therapy</i> , 2011, 11, 421-428.	3.4	7
82	Abstract 3991: miR-31 modulates tumor sensitivity to radiation in esophageal cancer by regulation of DNA repair genes. , 2011, , .		0
83	989 INVESTIGATING PROMOTER METHYLATION OF WNT SIGNALLING ANTAGONISTS IN PROSTATE CANCER. <i>European Urology Supplements</i> , 2010, 9, 310.	0.1	0
84	DNA mismatch repair and the transition to hormone independence in breast and prostate cancer. <i>Cancer Letters</i> , 2010, 291, 142-149.	7.2	18
85	DNA mismatch repair and the DNA damage response to ionizing radiation: Making sense of apparently conflicting data. <i>Cancer Treatment Reviews</i> , 2010, 36, 518-527.	7.7	70
86	Alterations in DNA Repair Efficiency are Involved in the Radioresistance of Esophageal Adenocarcinoma. <i>Radiation Research</i> , 2010, 174, 703-711.	1.5	65
87	Abstract 4904: Epigenetic discovery screen identifies SFRP2 as a novel biomarker of high grade prostate cancer. , 2010, , .		0
88	The HIF-1 β C1772T polymorphism may be associated with susceptibility to clinically localized prostate cancer but not with elevated expression of hypoxic biomarkers. <i>Cancer Biology and Therapy</i> , 2009, 8, 118-124.	3.4	50
89	Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells <i>in vitro</i> . <i>Journal of Gene Medicine</i> , 2009, 11, 169-179.	2.8	13
90	Recognition of O6MeG Lesions by MGMT and Mismatch Repair Proficiency may be a Prerequisite for Low-Dose Radiation Hypersensitivity. <i>Radiation Research</i> , 2009, 172, 405-413.	1.5	31

#	ARTICLE	IF	CITATIONS
91	The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate?. <i>Journal of Gene Medicine</i> , 2008, 10, 1032-1038.	2.8	6
92	Hypoxia in prostate cancer: A powerful shield against tumour destruction?. <i>Cancer Treatment Reviews</i> , 2008, 34, 313-327.	7.7	112
93	Radiation to control transgene expression in tumors. <i>Cancer Biology and Therapy</i> , 2007, 6, 1005-1012.	3.4	16
94	Achieving hypoxia-inducible gene expression in tumours. <i>Cancer Biology and Therapy</i> , 2005, 4, 365-370.	3.4	176